Charles River Laboratories sets 2030 financial targets and reaffirms 2026 guidance ranges

Charles River Laboratories International, Inc. (CRL) said Wednesday in a regulatory filing that it is hosting its Investor Day to outline its Pathway to Purpose strategy, which aims to modernize operations, expand scientific capabilities, and drive long-term profitable growth.

Key takeaways

• The company expects 2026 revenue and non-GAAP earnings per share at the upper ends of prior ranges.
• The Create the Future program targets over $300 million in cumulative savings from 2027 through 2030.
• Organic revenue growth is targeted at a 5% to 7% compound annual growth rate from 2027 to 2030.
• Non-GAAP operating margin is targeted at approximately 24% by 2030.

Strategy and long-term financial targets

The company introduced financial targets through 2030 in conjunction with the Investor Day presentation. Chief Executive Officer Birgit Girshick said in a press release, "Our Pathway to Purpose strategy is designed to strengthen Charles River's position as a leading scientific partner to the biopharmaceutical industry."

The modernization initiative, titled Create the Future, relies on simplified processes, increased automation, and digital enablement. Charles River expects the program to generate over $300 million in cumulative savings from 2027 through 2030. In addition, the company is expanding its Apollo cloud-based platform, which currently serves more than 18,000 client users.

2026 guidance and 2030 targets

The company reaffirmed its full-year 2026 financial guidance, noting that revenue and non-GAAP earnings per share are expected at the upper ends of prior ranges. The long-term financial targets exclude the impact of future acquisitions or divestitures.

Here is how the company's metrics compare across periods:

• Organic revenue growth: Upper end of 0% to 1% growth for 2026 guidance, and a 5% to 7% compound annual growth rate for the 2027 to 2030 target.
• Non-GAAP operating margin: 21.0% to 21.3% for 2026 guidance, and approximately 24% for the 2030 target.
• Non-GAAP earnings per share estimate: Upper end of $11.15 to $11.45 for 2026 guidance, and a low-double-digit compound annual growth rate for the 2027 to 2030 target.

Why it matters

The strategic update provides investors with long-term visibility into operational efficiency savings and revenue expectations through the end of the decade. Bioanalysis revenue is projected to grow organically at a high-single-digit compound annual growth rate to approximately $450 million in 2030, supported by organic and inorganic investments in vitro testing and related scientific solutions.

By the numbers

Investor Day execution

The live webcast and corresponding slide presentations are available on the investor relations section of the company website. Management will continue to evaluate the execution of the Pathway to Purpose initiatives as biopharmaceutical research and development demand evolves.